Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis
- PMID: 40334148
- PMCID: PMC12360034
- DOI: 10.1093/bjd/ljaf166
Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis
Abstract
Nemolizumab is a new biologic approved to treat atopic dermatitis. In this perspective piece, we use results from our living systematic review and network meta-analysis to provide perspective on the relative efficacy of nemolizumab compared with other approved targeted systemic treatments.
Conflict of interest statement
Conflicts of interest: The full Conflicts of Interest statement can be found in Appendix S2 (see Supporting Information).
Figures


References
-
- Silverberg JI, Wollenberg A, Reich A et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet 2024; 404:445–60. - PubMed
-
- Drucker AM, Lam M, Elsawi R et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol 2024; 190:184–90. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources